Objective The scope of the project is to generate a candidate drug targeting the inflammatory mediator High mobility group box 1 protein (HMGB1) to be used in treatment of stroke. The candidate drug will be validated in animal models, characterized and optimized for subsequent clinical development.Stroke remains a leading cause of death and disability throughout the world. Within EU, more than 500 000 persons die of stroke each year. Of those surviving stroke, 50% are left with physical or cognitive impairment and the total annual cost of stroke is estimated at Euro 27 billion.Stroke occurs as a consequence of hemorrhagic insult or artery occlusion due to underlying cardiovascular disease. Pivotal in beneficial treatment of stroke is instant intervention. Blood clot dissolution using recombinant tissue plasminogen activator is the only pharmacological treatment demonstrated to limit neurological damage in stroke, but is only effective for patients who present within 3 hours after stroke onset. Thus there is an unmet need for an efficacious therapy that can be administered within and beyond 3 hours to achieve neuroprotection. HMGB1, released during the cerebral ischemic event and the subsequent neuroinflammation, is a well-characterized mediator of inflammation. Beneficial effects of blocking HMGB1 is proven in preclinical stroke studies. The drug to be developed is an Affibody molecule binding to and neutralizing HMGB1. Affibody molecules are engineered proteins significantly smaller than antibodies and therefore having favorable biodistribution properties, and a history of being efficient and non-toxic in clinical trials. In this application, we describe a multidisciplinary research consortium with Europe´s leading scientists in HMGB1 research and in registry-based clinical trial and dissemination methodology. The consortium has unique potentials to bring a new treatment principle against cerebral stroke to clinical reality. Fields of science humanitieshistory and archaeologyhistorynatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health sciencesclinical medicinecardiologycardiovascular diseasesmedical and health sciencesbasic medicineneurologystroke Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Topic(s) HEALTH.2013.2.4.2-1 - Discovery research to reveal novel targets for cardiovascular disease treatment Call for proposal FP7-HEALTH-2013-INNOVATION-1 See other projects for this call Funding Scheme CP-FP - Small or medium-scale focused research project Coordinator KAROLINSKA INSTITUTET Address Nobels vag 5 17177 Stockholm Sweden See on map Region Östra Sverige Stockholm Stockholms län Activity type Higher or Secondary Education Establishments Administrative Contact Caroline Hamilton (Mrs.) Links Contact the organisation Opens in new window Website Opens in new window EU contribution No data Participants (5) Sort alphabetically Sort by EU Contribution Expand all Collapse all AFFIBODY AB Sweden EU contribution € 3 121 291,00 Address Gunnar asplunds alle 24 171 63 Solna See on map Region Östra Sverige Stockholm Stockholms län Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Fredrik Frejd (Prof.) Links Contact the organisation Opens in new window Other funding No data HMGBIOTECH SRL Italy EU contribution € 576 712,00 Address Piazzale gorini paolo 8 20133 Milano See on map Region Nord-Ovest Lombardia Milano Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Maura Casalgrandi (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Other funding No data THE UNIVERSITY OF LIVERPOOL United Kingdom EU contribution € 396 562,00 Address Brownlow hill 765 foundation building L69 7ZX Liverpool See on map Region North West (England) Merseyside Liverpool Activity type Higher or Secondary Education Establishments Administrative Contact Daniel Antoine (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Other funding No data UNIVERSITA VITA-SALUTE SAN RAFFAELE Italy EU contribution € 454 073,60 Address Via olgettina 58 20132 Milano See on map Region Nord-Ovest Lombardia Milano Activity type Higher or Secondary Education Establishments Administrative Contact Maria Rosa Pedrazzi (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Other funding No data CHARITE - UNIVERSITAETSMEDIZIN BERLIN Germany EU contribution € 379 794,00 Address Chariteplatz 1 10117 Berlin See on map Region Berlin Berlin Berlin Activity type Higher or Secondary Education Establishments Administrative Contact Karen Gertz (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Other funding No data
